GLIOBLAST-13: A NOVEL ANTI-BRAIN TUMOR THERAPEUTIC

GLIOBLAST-13：一种新型抗脑肿瘤治疗药物

• 批准号: 6210670
• 负责人: LYNN W MAINES
• 金额: $ 10万
• 依托单位: TARGEPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-03 至 2002-02-02
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6210670
• 关键词: Rodentias; antineoplastics; brain neoplasms; dosage; drug adverse effect; drug screening /evaluation; histopathology; nonhuman therapy evaluation; pharmacokinetics

DESCRIPTION: (Verbatim from the Applicant's Abstract) The aim of the project is to perform pre-clinical toxicology of a novel anti-brain tumor drug candidate, Glioblast-13. Glioblast-13 has been uniquely designed to kill specifically cancer cells while sparing normal tissues. In previous studies, Glioblast-13 showed prominent anti-tumor activity in vivo. The current experiments will establish the maximum tolerated dose (MTD) in rodents receiving Glioblast-13 intracranially and intravenously. The MTD will be the LD10 established in treated animals. In addition, normal tissues of the central nervous system and 22 peripheral organs will be analyzed by histopathology for the evidence of toxicity. In particular, the liver will be observed for general signs of toxicity and reversibility of the damage, if this occurs. These studies will enable us to prepare an IND application to the FDA for the initial clinical trials to be conducted in patients with incurable brain tumors. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（逐字从申请人的摘要）该项目的目的是 为了进行新型抗脑肿瘤候选药物的临床前毒理学， 胶质母细胞-13。胶质母细胞-13被独特地设计成 癌细胞而不伤害正常组织。在以前的研究中，胶质母细胞-13 显示出显著的体内抗肿瘤活性。目前的实验将 确定啮齿类动物接受Glioblast-13的最大耐受剂量（MTD） 颅内和静脉注射。MTD将是确定的LD 10， 对待动物。此外，中枢神经系统的正常组织和 将通过组织病理学分析22个外周器官的证据， 毒性特别是，将观察肝脏的一般体征， 毒性和可逆性的损害，如果发生这种情况。这些研究将 使我们能够准备IND申请FDA的初步临床 在患有无法治愈的脑肿瘤的患者中进行试验。 拟议商业应用：不可用